This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
BioPharma Drive: Drug Pricing
SEPTEMBER 19, 2023
AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.
313 
Drug Target Review
DECEMBER 20, 2024
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
128
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
DECEMBER 10, 2023
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. This is the story of how it came to be.
357 
BioPharma Drive: Drug Pricing
NOVEMBER 8, 2023
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
327 
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
313 
BioPharma Drive: Drug Pricing
OCTOBER 23, 2023
The Swiss pharmaceutical company has agreed to buy Televant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.
167 
BioPharma Drive: Drug Pricing
NOVEMBER 28, 2023
Tuesday’s deal signals the pharmaceutical giant's confidence in Avidity Biosciences and its so-called antibody oligonucleotide conjugates.
167 
Drug Target Review
MARCH 3, 2025
The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. “For diseases like Parkinson’s, it’s more than sufficient,” he explains.
52 
BioPharma Drive: Drug Pricing
DECEMBER 5, 2023
The company expects its pharmaceutical division to deliver 20 new medicines through the end of the decade, including several it believes could earn peak annual sales of more than $5 billion.
167 
BioPharma Drive: Drug Pricing
FEBRUARY 12, 2024
European venture firm Medicxi built the startup by combining six of its portolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.
157 
Drug Target Review
OCTOBER 11, 2023
Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.
113 
DrugBank
OCTOBER 4, 2024
Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.
Drug Target Review
MARCH 12, 2024
Scientists from the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego have discovered thousands of bile acids. The study’s findings offer new insights into the biochemical language microbes use to influence distant organ systems, which could revolutionise the way researchers approach disease.
111 
Drug Patent Watch
DECEMBER 12, 2024
This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.
94 
BioPharma Drive: Drug Pricing
APRIL 5, 2024
The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.
167 
Drug Target Review
OCTOBER 30, 2024
Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first.
105 
BioPharma Drive: Drug Pricing
MARCH 28, 2024
Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior head Claudia Ulbrich.
157 
Drug Patent Watch
DECEMBER 9, 2024
In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”
97 
SCIENMAG: Medicine & Health
OCTOBER 31, 2023
— A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University has received Food and Drug Administration (FDA) approval for the treatment of patients with Duchenne muscular dystrophy (DMD), a common genetic disease that mostly affects young boys. BINGHAMTON, N.Y.
83 
Conversations in Drug Development Trends
MAY 14, 2024
By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research. Common goals empower change.
81 
Drug Patent Watch
JULY 27, 2021
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong. The FDA is….
SCIENMAG: Medicine & Health
FEBRUARY 26, 2024
DCM is the leading cause of heart failure in patients with chronic diabetes. However, the underlying mechanisms of DCM are poorly understood, and treatment options are limited. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system.
75 
Drug Target Review
SEPTEMBER 9, 2024
functions to reset the immune system and potentially provide remission for allergic diseases? In allergic diseases, APCs identify and present unknown antigens to the immune system. This can lead to inadequate long-term effectiveness with low rates of disease remission. They also require frequent administration.
64 
LifeSciVC
JULY 17, 2024
By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.
Cytel
APRIL 10, 2024
Orphan drug designation is a regulatory status granted to pharmaceuticals developed for the treatment of rare diseases. It provides incentives to encourage the research, development, and approval of therapies targeting small patient populations.
59 
Drug Target Review
JUNE 5, 2024
How do you prioritise which therapeutic areas or diseases to focus on in your drug discovery efforts? About the author James Graham, CEO of Recce Pharmaceuticals Recce Pharmaceuticals. James Graham is the CEO of Recce Pharmaceuticals.
Drug Target Review
JANUARY 8, 2024
It is no mystery that as we age our health starts to deteriorate, and we become increasingly susceptible to diseases. Through years of scientific exploration and research, we now know there are several biological changes that make our bodies more susceptible to disease or injury, and we can target those with therapeutic interventions.
145 
Drug Discovery Today
JULY 30, 2020
Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases
100 
Drug Discovery Today
APRIL 20, 2023
Global integrated drug discovery company, Sygnature Discovery and global healthcare group Daewoong Pharmaceutical, have entered into a research collaboration agreement to accelerate the discovery of a novel small molecule to target autoimmune disease.
113 
Drug Target Review
JUNE 3, 2024
How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.
49 
SCIENMAG: Medicine & Health
AUGUST 21, 2023
professor of pharmaceutical sciences in the Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences and of pharmacology in Wayne State’s School of Medicine, received a $3 million, five-year award from the National Institute of Environmental Health Sciences of the National Institutes of Health.
80 
Drug Patent Watch
JANUARY 19, 2024
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.
Drug Patent Watch
SEPTEMBER 28, 2023
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.
Drug Channels
JUNE 14, 2022
The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations. But as I explain, the study’s headline conclusion is highly misleading.
98 
Broad Institute
NOVEMBER 25, 2024
Ladders to Cures (L2C) Accelerator By Maria Nemchuk November 25, 2024 Breadcrumb Home Ladders to Cures (L2C) Accelerator The Ladders to Cures (L2C) Accelerator aims to catalyze progress across the research ecosystem and accelerates advances leading to treatments and cures for patients with rare genetic diseases.
Drug Target Review
AUGUST 6, 2024
A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. Oncology also offers high returns and the opportunity to address severe, life-threatening conditions.
119 
The Premier Consulting Blog
NOVEMBER 6, 2024
Inhaled combination products (ICP) have emerged as a significant advancement in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary conditions. The goal of ICPs is to improve the quality of life for patients suffering from chronic respiratory diseases.
52 
Drug Target Review
JULY 5, 2023
While we are housed within a nanoscience centre, we enable microscopy techniques which can be used for much more than just nanoscience; rather, most of our users are medical and biological researchers doing things like designing new drug delivery vehicles, researching artificial tissue constructs and xenografts, or investigating disease and cancer (..)
104 
Crown Bioscience
NOVEMBER 11, 2024
The use of biomarkers has transformed the pharmaceutical industry by allowing researchers to develop therapies that target specific pathways in diseases. These can be proteins, genes, or other molecules that signal an abnormal or normal process in the body.
Broad Institute
DECEMBER 18, 2023
Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. Studies of Alzheimer's disease are teaching us that it's possible to measure some clinically important CSF biomarkers in blood.
130 
DrugBank
DECEMBER 18, 2024
A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). These interventions target a broad spectrum of medical conditions, encompassing chronic diseases and even substance abuse. Healthcare providers also stand to gain significantly from DTx adoption.
Drug Target Review
JULY 5, 2023
Cells are the units of life, yet they also drive disease. By applying AI/ML to the evolving gamut of single-cell technologies, we can better understand how cells transition from a state of health to disease. This new approach to drug discovery uncovers novel biology, even in diseases with no known targets.
98 
DrugBank
JANUARY 22, 2025
Environmental Impacts of Traditional Pharmaceutical Production Traditional pharmaceutical manufacturing is complex, with each phase contributing to environmental degradation. The extraction and synthesis of active pharmaceutical ingredients (API) utilize vast amounts of water and energy.
Drug Patent Watch
JULY 27, 2023
Orphan drug exclusivity is granted to drugs addressing rare ‘orphan diseases’ — those affecting fewer than 200,000 Americans. The FDA is… The post Pharmaceutical companies with the most orphan drugs appeared first on DrugPatentWatch - Make Better Decisions. The protection granted to orphan drugs is quite strong.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content